Ariana Pelosci is an editor at Cancer Network.
Promising Activity in MSS CRC with Innovative Drug Combined with Bevacizumab and Chemotherapy
January 20th 2024In the DeFianCe trial, the combination of DKN-01 with bevacizumab and chemotherapy is being investigated to assess the potential clinical benefits for patients diagnosed with microsatellite stable colorectal adenocarcinoma.
Single and Dual-Target D8 CAR T Cells Show Tolerability, Efficacy in R/R MM
December 10th 2023Investigators in the MCARTY study reported safety and high response rates in a small number of patients with relapsed/refractory multiple myeloma who received chimeric antigen receptor T-cell therapy designed with a new process to target the D8 binder, meant to improve efficacy in targeting BCMA.
Improved PFS in Advanced Ovarian Cancer With Senaparib vs Placebo
October 20th 2023The phase 3 FLAMES trial results demonstrated an improvement in progression-free survival with senaparib monotherapy vs placebo, regardless of patient subgroup, in patients with newly diagnosed, advanced ovarian cancer.
Real-World Study of Teclistamab Matches MajesTec-1 Efficacy Data in RRMM
September 29th 2023According to data presented at IMS 2023, a real-world analysis showed that teclistamab demonstrated comparable efficacy to the results observed in the phase 2 MajesTec-1 trial for patients with relapsed/refractory multiple myeloma.
Lenalidomide/ Rituximab Extends 5-Year PFS on R/R Indolent Non-Hodgkin Lymphoma
December 11th 2022Five-year follow up results from the phase 3 AUGMENT trial show that lenalidomide plus rituximab produced enhanced progression-free survival in patients with relapsed/refractory indolent non-Hodgkin lymphoma.
Evaluating Effective Treatment Options and Strategies for Relapsed/Refractory Mantle Cell Lymphoma
October 15th 2022At the 2022 NCCN annual congress, Tycel Phillips, MD, discussed different strategies that can be effective as second-line treatments in various patients who have relapsed/refractory mantle cell lymphoma.
Tucatinib Added to First-Line Maintenance Under Investigation in HER2+ Metastatic Breast Cancer
June 9th 2022The addition of tucatinib to standard of care maintenance in the first-line setting for patients with HER2-positive metastatic breast cancer will be examined in the ongoing phase 3 HER2CLIMB-05 trial.
Pembrolizumab Alone Shows Best Response in NSCLC With 90% or Higher PD-L1 Expression
June 7th 2022Treatment with pembrolizumab monotherapy demonstrated the best response in patients with non–small cell lung cancer and a PD-L1 tumor proportion score of 90% or more, according to a correlative analysis conducted with 3-years of follow-up.